[Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases].
Most undesired side effects in therapy with non-steroidal antiinflammatory drugs (NSAID) mainly effect the gastric and duodenal mucosa. The radioimmunological determination of pepsinogen A and C (pepsinogen group I and II) is qualified for inclusion of the functional and morphologic state of the gastroduodenal mucosa. By determination of the pepsinogens group A and C the influence and the gastroduodenal compatibility of the non-steroidal antiinflammatory drug lonazolac Ca (LCa) [Irritren] were examined in a dosage of 600 mg/d during a 2-weeks therapy. 31 patients with various painful rheumatic diseases and 10 healthy probands as a control group were examined. The results show that the treatment with LCa did not significantly effect mean and median of pepsinogen A- and -C levels in serum. Only in 3.7% of the cases a contemporary increase of pepsinogen A and C occurred, which could be estimated as a beginning superficial gastritis. In addition the beneficial clinical efficacy of LCa was documented by a significant decrease of a tripartite pain score from 2.1 to 1.4. The results point to a very good proportion of clinical efficacy and gastroduodenal side-effects of LCa.